2007 NSTI Nanotechnology Conference and Trade Show - Nanotech 2007 - 10th Annual

Differential Uptake of PEG-Silica-FITC Nanoparticles by Human Breast Cancer Cells and Normal Human Breast Epithelial Cells

N. Iwakuma, P. Sharma, M.J. Delano, L.L. Moldawer, B.M. Moudgil and S.R. Grobmyer
University of Florida, US

silica nanoparticles, breast cancer, normal breast epithelial cells, cellular uptake, flow cytometry

Background: An understanding of uptake of nanoparticles (NPs) by human cancer cells and non-cancer cells is important for the development of NPs as novel cancer therapeutic and diagnostic agents. Hypothesis: Uptake of NPs is increased in human breast cancer cells compared to normal human breast epithelial cells. Methods: PEGylated-FITC silica NPs (150nm, [1.18mg/mL]) were synthesized. Human breast cancer cell lines (MCF-7, BT474) and normal human breast epithelial cells were (MCF10A) cultured. Cells were exposed to NPs for 24h. A quantitative analysis (Flow-Cytometry) and qualitative analysis of cellular uptake (Fluorescence microscopy) were performed. Results: Exposure of cells to NPs did not affect cell viability. After incubation of cells with 20 l of NPs, increased uptake of PEG-silica-FITC NPs was seen in cancer cells (MCF-7, 18.5%; BT474, 16.8%) compared to non-cancer cells (MCF-10A, 9.9%). Incubation of cells with 40 l of NPs demonstrated that uptake of NPs is dose related and confirmed preferential uptake of NPs by cancer cells (MCF-7, 27.3%; BT474, 25.2%) compared to non-cancer cells (MCF-10A, 12.3%). Conclusion: Human breast cancer cells demonstrate increased uptake of NPs compared to normal human breast epithelial cells. This observation has important implications for the development of NPs as cancer therapeutic and/or diagnostic agents.

Back to Program

Sessions Sunday Monday Tuesday Wednesday Thursday Authors Keywords

Nanotech 2007 Conference Program Abstract


Names, and logos of other organizations are the property of those organizations and not of NSTI.
This event is not open to the general public and NSTI reserves the right to refuse admission and participation to any individual.